Position in GRFS
as of Jun 30, 2026
· filed Aug 6, 2026
Position Value
$14,542
+$12,230 QoQ
Shares Held
2,054
+927.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#123
of 164 holders
Holding Since
Mar 2022
9 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in GRFS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Clearstead Advisors, LLC holds $207,269,806 across 16 Drug Manufacturers - General names. GRFS ranks #15 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
55,467 | $66,528,789 | |
| 2 | JNJ |
Johnson & Johnson
|
234,177 | $59,473,932 | |
| 3 | ABBV |
AbbVie Inc.
|
111,021 | $27,937,324 | |
| 4 | AMGN |
Amgen Inc
|
40,211 | $14,561,207 | |
| 5 | MRK |
Merck & Co., Inc.
|
112,376 | $14,440,316 | |
| 6 | BMY |
Bristol Myers Squibb Co
|
128,389 | $7,397,774 | |
| 7 | PFE |
Pfizer Inc
|
197,145 | $4,747,251 | |
| 8 | NVS |
Novartis AG
|
25,239 | $3,955,456 |
All Filings in GRFS
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $14,542 | 2,054 | Shares | Sole | 2026-08-06 | |
| 2023-12-31 | $2,312 | 200 | Shares | Sole | 2024-02-12 | |
| 2023-09-30 | $1,828 | 200 | Shares | Sole | 2023-11-07 | |
| 2023-06-30 | $1,832 | 200 | Shares | Sole | 2023-08-07 | |
| 2023-03-31 | $1,474 | 200 | Shares | Sole | 2023-05-09 | |
| 2022-12-31 | $1,700 | 200 | Shares | Sole | 2023-02-14 | |
| 2022-09-30 | $1,232 | 200 | Shares | Sole | 2022-11-15 | |
| 2022-06-30 | $2,376 | 200 | Shares | Sole | 2022-08-12 | |
| 2022-03-31 | $2,336 | 200 | Shares | Sole | 2022-05-04 | |
| No filing history on record for this holder in this stock. | ||||||